Hypofractionated radiotherapy combined with lenalidomide improves systemic antitumor activity in mouse solid tumor models
Kateryna Onyshchenko, Ren Luo, Xi Rao, Xuanwei Zhang, Simone Gaedicke, Anca-Ligia Grosu, Elke Firat, Gabriele Niedermann
Abstract
We demonstrate that lena can augment the hRT-induced abscopal effect in mouse solid tumor models in a CD8 T cell- and IFN-I-dependent manner, correlating with enhanced anti-tumor CD8 T cell immunity, DC cross-presentation, and TA-HEC numbers. Our findings may be helpful for the planning of clinical trials in (oligo)metastatic patients.
Topics & Concepts
LenalidomideSolid tumorCancer researchMedicineRadiation therapyPharmacologyOncologyInternal medicineMultiple myelomaCancerCancer, Hypoxia, and MetabolismProtein Degradation and InhibitorsCancer therapeutics and mechanisms